This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Digoxin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Digoxin is a drug that is used primarily to slow the ventricular rate in chronic atrial fibrillation. The use of digoxin may be dangerous in hypertrophic obstructive cardiomyopathy and Wolff-Parkinson-White syndrome.

Digoxin has a weak positive inotropic effect and may be used in the treatment of heart failure in selected patients. In these patients digoxin and ACE inhibitors are usually used in combination.

In patients with atrial fibrillation digoxin may be helpful in the symptomatic treatment of heart failure: by controlling the ventricular rate, and thus improving ventricular filling, the myocardium is at a better position on the Frank-Starling curve. However there is no evidence suggesting reduction in mortality in patients who use digoxin (1).

Digoxin also upregulates the baroreceptor reflex and so has a further positive inotropic effect.

Digoxin has a narrow therapeutic ratio. Patients with poor renal function, heart failure and diuretic-induced hypokalaemia are more likely to suffer digoxin toxicity.

The summary of product characteristics should be consulted before prescribing this drug.

Reference:

  • 1) British Heart Foundation (Factfile 7/2001).The use of digoxin.
  • (2) Smith TW (1988). Digitalis: mechanism of action and clinical use. NEJM, 318, 358-65.
  • (3) BMJ (1993), 306, 48-51

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.